JP2012504122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012504122A5 JP2012504122A5 JP2011529021A JP2011529021A JP2012504122A5 JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5 JP 2011529021 A JP2011529021 A JP 2011529021A JP 2011529021 A JP2011529021 A JP 2011529021A JP 2012504122 A5 JP2012504122 A5 JP 2012504122A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- independently
- aliphatic
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000001931 aliphatic group Chemical group 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 22
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 125000003118 aryl group Chemical group 0.000 claims 16
- 229910052799 carbon Inorganic materials 0.000 claims 10
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- 125000001072 heteroaryl group Chemical group 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003373 pyrazinyl group Chemical group 0.000 claims 7
- 125000004076 pyridyl group Chemical group 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 5
- 125000002947 alkylene group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002950 monocyclic group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 3
- 150000008064 anhydrides Chemical class 0.000 claims 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 3
- 125000005434 dihydrobenzoxazinyl group Chemical group O1N(CCC2=C1C=CC=C2)* 0.000 claims 3
- 150000002148 esters Chemical class 0.000 claims 3
- 125000001624 naphthyl group Chemical group 0.000 claims 3
- -1 tetrahydroquinoxalinyl Chemical group 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 239000008139 complexing agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19461408P | 2008-09-29 | 2008-09-29 | |
| US61/194,614 | 2008-09-29 | ||
| PCT/US2009/005324 WO2010036357A1 (en) | 2008-09-29 | 2009-09-25 | Derivatives of 1-amino-2-cyclobutylethylboronic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085803A Division JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012504122A JP2012504122A (ja) | 2012-02-16 |
| JP2012504122A5 true JP2012504122A5 (cg-RX-API-DMAC10.html) | 2012-11-15 |
| JP5736314B2 JP5736314B2 (ja) | 2015-06-17 |
Family
ID=41426361
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011529021A Active JP5736314B2 (ja) | 2008-09-29 | 2009-09-25 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
| JP2015085803A Pending JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
| JP2016199804A Pending JP2017025091A (ja) | 2008-09-29 | 2016-10-11 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015085803A Pending JP2015143264A (ja) | 2008-09-29 | 2015-04-20 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
| JP2016199804A Pending JP2017025091A (ja) | 2008-09-29 | 2016-10-11 | 1−アミノ−2−シクロブチルエチルボロン酸の誘導体 |
Country Status (25)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2623113B1 (en) | 2005-11-09 | 2017-05-31 | Onyx Therapeutics, Inc. | Compound for enzyme inhibition |
| NZ597545A (en) | 2006-06-19 | 2013-07-26 | Proteolix Inc | Peptide epoxyketones for proteasome inhibition |
| CA2701778C (en) | 2007-10-04 | 2018-09-11 | Onyx Therapeutics, Inc. | Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides |
| SI2318419T2 (sl) | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | ペプチドエポキシケトンを用いた併用療法 |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| WO2011060179A1 (en) | 2009-11-13 | 2011-05-19 | Onyx Therapeutics, Inc | Use of peptide epoxyketones for metastasis suppression |
| AU2011223795B2 (en) | 2010-03-01 | 2015-11-05 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
| EP2776586B1 (en) | 2011-11-11 | 2018-03-07 | Millennium Pharmaceuticals, Inc. | Biomarkers of response to proteasome inhibitors |
| CN104039328B (zh) | 2011-11-11 | 2018-10-09 | 米伦纽姆医药公司 | 对蛋白酶体抑制剂的反应的生物标记 |
| SG10201605152SA (en) | 2011-12-22 | 2016-08-30 | Ares Trading Sa | Alpha-amino boronic acid derivatives, selective immunoproteasome inhibitors |
| WO2013112601A1 (en) | 2012-01-24 | 2013-08-01 | Millennium Pharmaceuticals, Inc. | Methods of treatment of cancer |
| WO2014011695A2 (en) | 2012-07-09 | 2014-01-16 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
| MX2015006715A (es) * | 2012-12-03 | 2015-08-14 | Hoffmann La Roche | Compuestos de acido triazolboronico sustituido. |
| US20160250238A1 (en) | 2013-10-03 | 2016-09-01 | Millennium Pharmaceuticals, Inc. | Method for the Prophylaxis or Treatment of Systemic Lupus Erythematosus and/or Lupus Nephritis |
| ES2748434T3 (es) | 2014-01-10 | 2020-03-16 | Univ Cornell | Dipéptidos como inhibidores de inmunoproteasomas humanos |
| UA121389C2 (uk) | 2014-05-20 | 2020-05-25 | Мілленніум Фармасьютікалз, Інк. | Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії |
| WO2016022955A1 (en) | 2014-08-07 | 2016-02-11 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| US11202817B2 (en) | 2014-08-18 | 2021-12-21 | Cornell University | Dipeptidomimetics as inhibitors of human immunoproteasomes |
| US10640520B2 (en) * | 2014-10-01 | 2020-05-05 | Merck Patent Gmbh | Boronic acid derivatives |
| EP3201208B1 (en) * | 2014-10-01 | 2021-03-24 | Merck Patent GmbH | Boronic acid derivatives |
| AU2015327345B9 (en) * | 2014-10-01 | 2020-06-18 | Merck Patent Gmbh | Boronic acid derivatives |
| EP3201207B1 (en) * | 2014-10-01 | 2021-02-24 | Merck Patent GmbH | Boronic acid derivatives |
| EP4006012A1 (en) | 2015-10-15 | 2022-06-01 | Cornell University | Proteasome inhibitors and uses thereof |
| JP7164521B2 (ja) | 2016-06-21 | 2022-11-01 | オリオン・オフサルモロジー・エルエルシー | 炭素環式プロリンアミド誘導体 |
| JP7179721B2 (ja) | 2016-06-21 | 2022-11-29 | オリオン・オフサルモロジー・エルエルシー | 複素環式プロリンアミド誘導体 |
| WO2018160717A1 (en) | 2017-02-28 | 2018-09-07 | Mayo Foundation For Medical Education And Research | Compounds and methods for treating cancer |
| WO2019075252A1 (en) | 2017-10-11 | 2019-04-18 | Cornell University | PEPTIDOMIMETIC INHIBITORS OF PROTEASOME |
| US11243207B2 (en) | 2018-03-29 | 2022-02-08 | Mayo Foundation For Medical Education And Research | Assessing and treating cancer |
| ES2960987T3 (es) | 2019-04-12 | 2024-03-07 | Riboscience Llc | Derivados de heteroarilo bicíclicos como inhibidores de la ectonucleótido pirofosfatasa fosfodiesterasa 1 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ203706A (en) | 1982-04-22 | 1986-03-14 | Squibb & Sons Inc | Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment |
| US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
| US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
| EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
| US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
| DE3827340A1 (de) * | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
| EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
| US5935944A (en) | 1993-09-10 | 1999-08-10 | Neutron Technology Corporation | Formulation for I.V. administration of the boron delivery drug, boronophenylalanine (BPA) |
| US5492900A (en) | 1993-09-10 | 1996-02-20 | Neutron Technology Corporation | Method for enhancing the solubility of the boron delivery drug, boronophenylalanine (BPA) |
| US6060462A (en) | 1993-10-20 | 2000-05-09 | Dupont Pharmaceuticals Company | Electrophilic peptide analogs as inhibitors of trypsin-like enzymes |
| US5574017A (en) | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
| US6271199B2 (en) | 1997-02-15 | 2001-08-07 | Millennium Pharmaceuticals, Inc. | Treatment of infarcts |
| AU9580098A (en) | 1997-09-25 | 1999-04-12 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors, ubiquitin pathway inhibitors or agents that interfere with the activation of nf-(k)b via the ubiquitin proteasome pathway to treat inflammatory and autoimmune diseases |
| CA2314259A1 (en) | 1997-12-16 | 1999-06-24 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
| US6169076B1 (en) | 1999-03-31 | 2001-01-02 | Glcosyn Pharmaceuticals, Inc. | P-Boronophenylalanine complexes with fructose and related carbohydrates and polyols |
| WO2001002424A2 (en) | 1999-07-07 | 2001-01-11 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
| US6846806B2 (en) | 2000-10-23 | 2005-01-25 | Bristol-Myers Squibb Company | Peptide inhibitors of Hepatitis C virus NS3 protein |
| CA2435146C (en) | 2001-01-25 | 2011-03-29 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Formulation of boronic acid compounds |
| EP1399468B1 (en) | 2001-05-30 | 2006-02-15 | Novartis AG | 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
| WO2003033507A1 (en) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Benzylmalonic acid derivatives and proteasome inhibitors contaiing the same |
| EP1463719A2 (en) | 2002-01-08 | 2004-10-06 | Eisai Co., Ltd | Eponemycin and epoxomicin analogs and uses thereof |
| AU2003223930A1 (en) | 2002-06-14 | 2003-12-31 | Novo Nordisk A/S | Pharmaceutical use of boronic acids and esters thereof |
| US20060084592A1 (en) | 2002-09-09 | 2006-04-20 | Trigen Limited | Peptide boronic acid inhibitors |
| TW200418791A (en) | 2003-01-23 | 2004-10-01 | Bristol Myers Squibb Co | Pharmaceutical compositions for inhibiting proteasome |
| US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| US7223745B2 (en) | 2003-08-14 | 2007-05-29 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| TWI345465B (en) * | 2003-08-14 | 2011-07-21 | Cephalon Inc | Proteasome inhibitors and methods of using the same |
| GB0405267D0 (en) | 2004-03-09 | 2004-04-21 | Trigen Ltd | Compounds |
| ES2899606T3 (es) | 2004-03-30 | 2022-03-14 | Millennium Pharm Inc | Síntesis de compuestos de ésteres y ácidos borónicos |
| US7468383B2 (en) | 2005-02-11 | 2008-12-23 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
| CN101247799B (zh) | 2005-07-05 | 2013-03-27 | 塔夫茨大学信托人 | 成纤维细胞活化蛋白α的抑制剂 |
| WO2007089618A2 (en) | 2006-01-27 | 2007-08-09 | Phenomix Corporation | Hepatitis c serine protease inhibitors and uses therefor |
| WO2009006473A2 (en) | 2007-07-05 | 2009-01-08 | Trustees Of Tufts College | Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| KR20140042933A (ko) | 2007-08-06 | 2014-04-07 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 프로테아좀 억제제 |
| US7442830B1 (en) | 2007-08-06 | 2008-10-28 | Millenium Pharmaceuticals, Inc. | Proteasome inhibitors |
| SI2318419T2 (sl) | 2008-06-17 | 2025-10-30 | Takeda Pharmaceutical Company Limited | Spojine boronat estra in njihovi farmacevtski sestavki |
| AU2011235227B2 (en) | 2010-03-31 | 2016-09-08 | Millennium Pharmaceuticals, Inc. | Derivatives of 1-amino-2-cyclopropylethylboronic acid |
-
2009
- 2009-09-12 AR ARP090103760A patent/AR075090A1/es not_active Application Discontinuation
- 2009-09-25 EA EA201170508A patent/EA030539B1/ru not_active IP Right Cessation
- 2009-09-25 NZ NZ606001A patent/NZ606001A/en not_active IP Right Cessation
- 2009-09-25 KR KR1020117009732A patent/KR101739470B1/ko not_active Expired - Fee Related
- 2009-09-25 AU AU2009297113A patent/AU2009297113B2/en not_active Ceased
- 2009-09-25 US US12/586,650 patent/US8664200B2/en not_active Expired - Fee Related
- 2009-09-25 WO PCT/US2009/005324 patent/WO2010036357A1/en not_active Ceased
- 2009-09-25 CR CR20160475A patent/CR20160475A/es unknown
- 2009-09-25 CA CA2739375A patent/CA2739375C/en active Active
- 2009-09-25 MX MX2011003317A patent/MX2011003317A/es active IP Right Grant
- 2009-09-25 UA UAA201105450A patent/UA105503C2/uk unknown
- 2009-09-25 NZ NZ592497A patent/NZ592497A/xx not_active IP Right Cessation
- 2009-09-25 SG SG2013073267A patent/SG194388A1/en unknown
- 2009-09-25 MY MYPI2011001392A patent/MY166653A/en unknown
- 2009-09-25 JP JP2011529021A patent/JP5736314B2/ja active Active
- 2009-09-25 CN CN201310475757.1A patent/CN103554143B/zh active Active
- 2009-09-25 EP EP09789372.1A patent/EP2346882B1/en active Active
- 2009-09-25 CN CN200980144074XA patent/CN102203103A/zh active Pending
- 2009-09-25 BR BRPI0919447A patent/BRPI0919447B8/pt not_active IP Right Cessation
- 2009-09-29 TW TW105105530A patent/TWI598352B/zh not_active IP Right Cessation
- 2009-09-29 TW TW098133005A patent/TW201024313A/zh unknown
-
2011
- 2011-03-25 CL CL2011000653A patent/CL2011000653A1/es unknown
- 2011-03-28 IL IL211983A patent/IL211983A0/en unknown
- 2011-03-28 DO DO2011000086A patent/DOP2011000086A/es unknown
- 2011-04-26 CR CR20110216A patent/CR20110216A/es unknown
- 2011-04-26 MA MA33796A patent/MA32729B1/fr unknown
- 2011-04-27 CO CO11051428A patent/CO6362015A2/es active IP Right Grant
- 2011-04-28 EC EC2011011011A patent/ECSP11011011A/es unknown
-
2012
- 2012-05-17 ZA ZA2012/03615A patent/ZA201203615B/en unknown
-
2014
- 2014-01-13 US US14/153,752 patent/US9771381B2/en not_active Expired - Fee Related
-
2015
- 2015-04-20 JP JP2015085803A patent/JP2015143264A/ja active Pending
-
2016
- 2016-10-11 JP JP2016199804A patent/JP2017025091A/ja active Pending
-
2017
- 2017-08-18 US US15/680,514 patent/US10035811B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2012146194A (ru) | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина | |
| JP2015511217A5 (cg-RX-API-DMAC10.html) | ||
| RU2012146819A (ru) | Ингибиторы аргиназы и их терапевтические применения | |
| JP2017505314A5 (cg-RX-API-DMAC10.html) | ||
| TW201039865A (en) | Lyophilized preparations of proteasome inhibitors | |
| JPH07108855B2 (ja) | 循環器治療薬として有用な酸化窒素―第一級アミン安定化コンプレックス | |
| JP2013544261A5 (cg-RX-API-DMAC10.html) | ||
| JP2013526501A5 (cg-RX-API-DMAC10.html) | ||
| JP2009519222A5 (cg-RX-API-DMAC10.html) | ||
| JP2014518882A5 (cg-RX-API-DMAC10.html) | ||
| RU2012146101A (ru) | Производные 1-амино-2-циклопропилэтилбороновой кислоты | |
| JP2017531624A5 (cg-RX-API-DMAC10.html) | ||
| JP2015501833A5 (cg-RX-API-DMAC10.html) | ||
| AR075090A1 (es) | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. | |
| JP2008533191A5 (cg-RX-API-DMAC10.html) | ||
| JP2014508814A (ja) | リチウム組成物 | |
| JP2022081630A (ja) | ベンゾアゼピン化合物含有凍結乾燥組成物 | |
| TR201908746T4 (tr) | Bir aktif içerik maddesi olarak tetrazol türevini içeren gelişmiş çözünürlüklü katı dispersiyonu. | |
| JP5086497B1 (ja) | ボロン酸化合物を含有したブロック共重合体を含む医薬組成物 | |
| RU2014133390A (ru) | Производные изохинолина и нафтиридина | |
| RU2013136861A (ru) | Новое производное индола или индазола или его соль | |
| RU2011142154A (ru) | Производные фосфлокуназола, их синтез и применение в препаратах длительного действия | |
| US20140072604A1 (en) | Block Copolymer For Intraperitoneal Administration Containing Anti-Cancer Agent, Micelle Preparation Thereof, And Cancer Therapeutic Agent Comprising The Micelle Preparation As Active Ingredient | |
| RU2015113959A (ru) | Индолины | |
| JP2018024648A (ja) | ボルテゾミブを含有する医薬製剤の製造方法 |